Epigenetic Therapy in Human Choriocarcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 28

PMID 24281181

Authors

Noriyuki Takai

Hisashi Narahara

Affiliations

Soon will be listed here.

Abstract

Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in choriocarcinoma cell lines. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating choriocarcinoma, with a special focus on preclinical studies.

References

Takai N, Ueda T, Nishida M, Nasu K, Narahara H . Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells. Int J Mol Med. 2007; 21(1):109-15. View

Gui C, Ngo L, Xu W, Richon V, Marks P . Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A. 2004; 101(5):1241-6. PMC: 337037. DOI: 10.1073/pnas.0307708100. View

Ruefli A, Ausserlechner M, Bernhard D, Sutton V, Tainton K, Kofler R . The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A. 2001; 98(19):10833-8. PMC: 58560. DOI: 10.1073/pnas.191208598. View

Berkowitz R, Goldstein D, Bernstein M . Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors. Gynecol Oncol. 1984; 19(2):173-81. DOI: 10.1016/0090-8258(84)90177-x. View

Cang S, Ma Y, Liu D . New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol. 2009; 2:22. PMC: 2695818. DOI: 10.1186/1756-8722-2-22. View

Haberland M, Montgomery R, Olson E . The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2008; 10(1):32-42. PMC: 3215088. DOI: 10.1038/nrg2485. View

Surwit E, Hammond C . Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980; 55(5):565-70. View

Strahl B, Allis C . The language of covalent histone modifications. Nature. 2000; 403(6765):41-5. DOI: 10.1038/47412. View

Xu W, Ngo L, Perez G, Dokmanovic M, Marks P . Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A. 2006; 103(42):15540-5. PMC: 1592530. DOI: 10.1073/pnas.0607518103. View

10.

Takai N, Kawamata N, Gui D, Said J, Miyakawa I, Koeffler H . Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer. 2004; 101(12):2760-70. DOI: 10.1002/cncr.20709. View

11.

Rahnama F, Shafiei F, Gluckman P, Mitchell M, Lobie P . Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology. 2006; 147(11):5275-83. DOI: 10.1210/en.2006-0288. View

12.

Gregorie C, Wiesen J, Magner W, Lin A, Tomasi T . Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence. J Reprod Immunol. 2009; 81(1):25-33. PMC: 2731570. DOI: 10.1016/j.jri.2009.02.009. View

13.

Marchion D, Munster P . Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007; 7(4):583-98. DOI: 10.1586/14737140.7.4.583. View

14.

Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon V . Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009; 2:31. PMC: 2731787. DOI: 10.1186/1756-8722-2-31. View

15.

Jenuwein T, Allis C . Translating the histone code. Science. 2001; 293(5532):1074-80. DOI: 10.1126/science.1063127. View

16.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

17.

Jones W, Cardinale C, Lewis Jr J . Management of high-risk gestational trophoblastic disease--the Memorial Hospital experience. Int J Gynecol Cancer. 1997; 7(1):27-33. DOI: 10.1046/j.1525-1438.1997.00409.x. View

18.

Takai N, Narahara H . Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem. 2007; 14(24):2548-53. DOI: 10.2174/092986707782023299. View

19.

Rosato R, Almenara J, Grant S . The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003; 63(13):3637-45. View

20.

Tan J, Cang S, Ma Y, Petrillo R, Liu D . Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010; 3:5. PMC: 2827364. DOI: 10.1186/1756-8722-3-5. View